AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29246960
Drug: omega‐3 ethyl‐ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega‐3 ethyl‐ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily)
Trial: 26036082
Drug: Standard combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combined treatment (including pharmacotherapy, massage, and therapeutic physical culture exercises)
Trial: 23143710
Drug: Twin-mix (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twin-mix (1.8 ml 2% lignocaine with 1:200,000 epinephrine + 1 ml of 4 mg dexamethasone)
Trial: 19837909
Drug: Cinacalcet 30
RxNorm normalized name: cinacalcet 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 30 mg twice daily, increasing to 50 mg twice daily during the 12-week titration if serum calcium levels were 10.3 mg/dl or higher
Trial: 16946029
Drug: Adenosine receptor
RxNorm normalized name: Adenosine receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine receptor antagonism with aminophylline (Aph)
Trial: 14724146
Drug: Omeprazole triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole triple therapy (HpE group)
Trial: 14724146
Drug: Omeprazole with
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole with placebo antibiotics (Hp+ group)
Trial: 9402119
Drug: Rectal tube
RxNorm normalized name: rectal tube
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal tube placement
Trial: 31780570
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg every 3 weeks, typically for ≤12 months) combined with front-line chemotherapy (carboplatin/paclitaxel)
Trial: 31780570
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg) with chemotherapy
Trial: 14727235
Drug: RCT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT plus amifostine (300 mg/m(2) daily intravenous infusion)
Trial: 1852797
Drug: Training twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training twice per week (n = 12)
Trial: 30862193
Drug: TX-004HR (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-004HR (4, 10, or 25 μg)
Trial: 28653345
Drug: Intravenous bimagrumab
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bimagrumab 30 mg/kg
Trial: 17307412
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration before transfer to catheterization laboratory (27 patients)
Trial: 17307412
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration immediately before PPCI (32 patients)
Trial: 11685730
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and exisulind combination therapy
Trial: 9059766
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with a low-calorie diet and metformin 1,700 mg/day
Trial: 30905926
Drug: Metformin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin combined group
Trial: 30905926
Drug: Insulin group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin group (Control)
Trial: 18500521
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg twice per day, 4 days before and on the day of chemotherapy (cohort 2)
Trial: 18500521
Drug: Dexamethasone 16
RxNorm normalized name: dexamethasone 16 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 16 mg twice per day, 4 days before and on the day of chemotherapy (cohort 3)
Trial: 16702889
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose venlafaxine ER (mean dose = 309 mg/d)
Trial: 16702889
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose venlafaxine ER (mean dose = 148 mg/d)
Trial: 16702889
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose venlafaxine ER
Trial: 16702889
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose venlafaxine ER
Trial: 8321736
Drug: All dosage
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosage groups of ramipril and enalapril
Trial: 3759915
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral dose of oxazepam in capsule form
Trial: 3759915
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral dose of oxazepam in tablet form
Trial: 27629738
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative antibiotic therapy (Group II, n = 25)
Trial: 22860693
Drug: Regular hypotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular hypotonic ORS (Na 60 mmol/L, glucose 78 mmol/L)
Trial: 18822473
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (per os or parenteral)
Trial: 10632230
Drug: Systemic behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic behavioral family therapy
Trial: 1973583
Drug: Dimethindene maleate
RxNorm normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethindene maleate (4 mg) intravenously injected
Trial: 18604074
Drug: Paracetamol syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol syrup
Trial: 3911962
Drug: Paracetamol suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol suppositories
Trial: 304522
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paracetamol with doxylaminsuccinate
Trial: 23623339
Drug: 4 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mcg/kg dexmedetomidine
Trial: 19154492
Drug: Non-invasive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive management (NIM) with immediate empirical antibiotic treatment (n = 34)
Trial: 16749654
Drug: EZE/SIMVA 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/20 mg
Trial: 17451425
Drug: EZE/SIMVA 10/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/40 mg
Trial: 17451425
Drug: ATV 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV 20 mg
Trial: 17451425
Drug: EZE/SIMVA 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/20 mg, EZE/SIMVA 10/40 mg, ATV 20 mg
Trial: 15070662
Drug: FLAG (Fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG (Fludarabine + ARA-C + G-CSF)
Trial: 15070662
Drug: AG (ARA-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG (ARA-C + G-CSF)
Trial: 11419672
Drug: Aminopenicillins at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminopenicillins at the correct dose
Trial: 7500752
Drug: High-dose traction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose traction
Trial: 9431610
Drug: Sham (low-dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sham (low-dose) traction
Trial: 8214532
Drug: Ropivacaine 1%
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1% (150 mg)
Trial: 8214532
Drug: Bupivacaine 0.75%
RxNorm normalized name: BUPivacaine 0.75% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.75% (112.5 mg)
Trial: 27580443
Drug: PSSIB (Palmar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSSIB (Palmar Subcutaneous Single Injection Block)
Trial: 27580443
Drug: DTIB (Dorsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIB (Dorsal 2 Injection Block)
Trial: 25141962
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm) applied five days a week before each radiotherapy session.
Trial: 20452927
Drug: Curriculum infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curriculum infusion (CI) in treatment classes
Trial: 20452927
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no curriculum infusion)
Trial: 16572301
Drug: Behavior observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior observation in training intervention agents
Trial: 14517785
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg intravenous cyclosporine
Trial: 14517785
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg intravenous cyclosporine
Trial: 10379634
Drug: Isradipine SRO
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine SRO (2.5 mg)
Trial: 10806134
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg)
Trial: 10379634
Drug: Spirapril (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril (6 mg)
Trial: 8884757
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg vincamine twice daily
Trial: 1647531
Drug: High compliance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High compliance enhancement group (wheat bran fiber supplement 18 g/day)
Trial: 1647531
Drug: Medium compliance
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium compliance enhancement group (wheat bran fiber supplement 18 g/day)
Trial: 1647531
Drug: Low compliance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low compliance enhancement group (wheat bran fiber supplement 18 g/day)
Trial: 6195201
Drug: 1% gamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gamma benzene hexachloride (GBH) lotion applied for 6 hours
Trial: 6195201
Drug: 1% gamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gamma benzene hexachloride (GBH) lotion applied for 12 to 24 hours
Trial: 6195201
Drug: 1% gamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gamma benzene hexachloride (GBH) lotion applied for 2 hours
Trial: 23314556
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (500 µg folic acid, 500 µg vitamin B12, 50 mg vitamin B6), 1200 IU vitamin D, and 456 mg calcium
Trial: 19817285
Drug: Local block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local block therapy (Group B)
Trial: 12732397
Drug: Oral ethinyl
RxNorm normalized name: ethinyl estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl estradiol
Trial: 12732397
Drug: Transdermal 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta-estradiol
Trial: 18989681
Drug: Parenteral testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral testosterone
Trial: 9039199
Drug: Butenafine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butenafine 1% cream applied once daily for 4 weeks
Trial: 30378087
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied once daily for 4 weeks
Trial: 3594491
Drug: Adjuvant oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oral Bestatin treatment (30 mg daily for at least 1 year)
Trial: 30782906
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg adrecizumab
Trial: 30782906
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg adrecizumab
Trial: 30782906
Drug: Adrecizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrecizumab (2 and 4 mg/kg)
Trial: 21305612
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (ESC and DUL)
Trial: 18223503
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (100 mL supplemented yogurt per day for 15 days)
Trial: 18223503
Drug: Control yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control yogurt (100 mL unsupplemented yogurt per day for 15 days)
Trial: 14562640
Drug: Unkei-to (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unkei-to (7.5 g/d)
Trial: 3898291
Drug: Thymopentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (50 mg, administered 3 times a week, subcutaneously for 6 weeks)
Trial: 3898291
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered 3 times a week, subcutaneously for 6 weeks)
Trial: 25407279
Drug: Lesogaberan 30
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 30 mg
Trial: 25407279
Drug: Lesogaberan 90
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 90 mg
Trial: 25407279
Drug: Lesogaberan 120
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 120 mg
Trial: 25407279
Drug: Lesogaberan 240
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan 240 mg
Trial: 23302735
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg mifepristone once a day for 2 days + 200 µg misoprostol 48 hours later (G1 group)
Trial: 23302735
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg mifepristone + 600 µg misoprostol 48 hours later (G2 group)
Trial: 16095463
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml 3% dextran 60 solution
Trial: 16095463
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml acetated Ringer's solution
Trial: 12034106
Drug: Aerosol measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol measles and rubella (MR) vaccine
Trial: 12034106
Drug: Subcutaneous measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous measles and rubella (MR) vaccine
Trial: 7555467
Drug: Meloxicam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (7.5 mg/day)
Trial: 7555467
Drug: Meloxicam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (15 mg/day)
Trial: 2258250
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg/day)
Trial: 2217669
Drug: Antibiotics before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics before the procedure
Trial: 6093240
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antibiotics)
Trial: 28707431
Drug: T. foenum‐graecum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. foenum‐graecum de‐husked seed extract, 600 mg per day for 12 weeks
Trial: 20079135
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 microg/kg bolus followed by continuous infusion of 0.1 microg x kg(‐1) x min(‐1)
Trial: 20079135
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 microg/kg bolus followed by continuous infusion of 0.1 microg x kg(‐1) x min(‐1)
Trial: 20079135
Drug: Sufentanil 0.1
RxNorm normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.1 microg/kg bolus followed by continuous infusion of 0.01 microg x kg(‐1) x min(‐1)
Trial: 15238028
Drug: Generation (participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generation (participants generated some study words, e.g., hot‐c__)
Trial: 15238028
Drug: Reading (participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading (participants read other study words, e.g., hot‐cold)
Trial: 12877377
Drug: Antibiotics (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (amoxicillin 750 mg x 2, doxycycline 100 mg x 2 or penicillin V 1500 mg x 2)
Trial: 7784724
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (1 mg/kg) administered via regular endotracheal tube (group 1)
Trial: 7784724
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (1 mg/kg) administered via suction-catheter deep endobronchially (group 2)
Trial: 7784724
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (1 mg/kg) administered via EDGAR-tube (group 3)
Trial: 7784724
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group 4) with regular endotracheal tube without lidocaine administration
Trial: 2113848
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms levonorgestrel (L‐NOG)
Trial: 31065703
Drug: GPM (GalliPro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPM (GalliPro Max/B. subtilis, 500 g/ton)
Trial: 31065703
Drug: GPT (GalliPro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPT (GalliPro Tect/B. licheniformis, 500 g/ton)
Trial: 28084890
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention group, median 1.8 h/week during adjuvant therapy (IQR 1.4-2.5)
Trial: 23402718
Drug: Counterconditioning (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counterconditioning (CC) in context A (AAA-COUNTER-group)
Trial: 23402718
Drug: Counterconditioning (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counterconditioning (CC) in context B (ABA-COUNTER-group)
Trial: 23402718
Drug: Counterconditioning (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counterconditioning (CC)
Trial: 22137072
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (weight of 121 kg)
Trial: 22137072
Drug: Actual body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual body weight (ABW)-based dosing (no upper limit)
Trial: 22137072
Drug: Ideal body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ideal body weight (IBW)-based dosing
Trial: 11352416
Drug: DDAVP (Desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (Desmopressin Acetate) administered preoperatively
Trial: 8044610
Drug: Chemotherapy (5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-fluorouracil, Adriamycin, and mitomycin)
Trial: 21133981
Drug: Control (postponed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (postponed periodontal treatment)
Trial: 17078443
Drug: Oral Benadryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Benadryl and Vitamin C plus local external application of 10% urea ointment
Trial: 15217172
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing (ODD) of gentamicin 5 mg/kg
Trial: 15217172
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing (TDD) of gentamicin 2.5 mg/kg
Trial: 11089713
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (41%)
Trial: 11089713
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (24%)
Trial: 11089713
Drug: Thiazide diuretics
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretics (17%)
Trial: 11089713
Drug: Beta-blockers (10%)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (10%)
Trial: 7911400
Drug: Lansoprazole 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15, 30, or 60 mg/day for 4 and 8 weeks
Trial: 2431908
Drug: meglumine diatrizoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meglumine diatrizoate at 306 mgI/ml
Trial: 2431908
Drug: iohexol at
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iohexol at 240 mgI/ml
Trial: 29708818
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of LI73014F2